GSK shares are trading lower after the company announced that it will cease further development of Camlipixant as a chronic cough treatment due to its failure to meet statistical significance in two clinical trials.

Benzinga Newsdesk www.benzinga.com Negative 89.0%

Neg 89% Neu 0% Pos 0%

GSK Plans To Stop Further Development Of In Refractory Chronic Cough As Camlipixant 25mg Twice Daily Failed To Meet Statistical Significance In CALM-1, CALM-2 Clinical Trials